UNSPSC 51263314: Trigevolol

This classification denotes a beta-adrenergic blocking agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier L2D8DE8S32. European Medicines Agency schedules Trigevolol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11294MIG. Trigevolol generally arises in the molecular formula C21H28N2O7.

UNSPSC 51263314 Trigevolol, a Commodity code, covers pharmaceutical products that state and local health agencies procure to support public health initiatives and community health programs. Recent solicitations show state and local governments buying naloxone and related drug-intervention systems, reflecting procurement focused on opioid response and harm-reduction services rather than the narrow pharmaceutical ingredient the code name suggests. The issuing bodies include county health departments and state health and human services commissions, with activity spanning health-focused purchasing for emergency response and pharmacy benefit program design. Work solicited includes bulk procurement of naloxone units for community distribution, safe drug deactivation systems for public health facilities, and exploratory vendor engagement around direct-to-manufacturer prescription sourcing models that bypass traditional pharmacy benefit manager channels.

Seminole County, Florida posted an IFB (IFB60459723LAS) on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with a response deadline of July 26, 2023, requiring quarterly deliveries to the County Community Health Building in Sanford with shipping included in vendor pricing and a two-year initial term plus optional one-year renewal. The Texas Health and Human Services Commission issued an RFI (HHS0017013) posted April 3, 2026, with a response deadline of April 3, 2026, to gather vendor capability information on direct-to-manufacturer prescription programs for self-insured health plans, exploring alternatives to traditional pharmacy benefit manager and group purchasing organization arrangements. Geographic activity centers on Florida and Texas, with both opportunities reflecting broader state and local interest in cost management and alternative sourcing models in pharmaceutical procurement.